Between 2000-2013 Sarah was based at the Kirby Institute, Faculty of Medicine, University of New South Wales where she lead several international, randomised controlled trials, across more than 60 centres in Australia, Asia, Europe and Latin America. i.e. ESPRIT, SILCAAT (Phase III interleukin-2 studies), START (’when to start Antiretroviral therapy’) and the Phase IV maraviroc (a CCR5 blocker) switch study, MARCH.
She joined the MRC CTU and Infection and Population Health institutes at UCL in September 2013, and continues to expand her interest in the optimisation of antimicrobial therapies for various infectious diseases including HIV. She is also an Honorary Consultant in Infectious Diseases, Central and North West London NHS Foundation Trust, and Honorary Associate Professor University of New South Wales, Sydney, Australia.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59.
Pett SL, McCarthy MC, Cooper DA, MacRae K, Tendolkar A, Norris R, Strizki JM, Williams KM, Emery S. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. Antivir Ther. 2009;14(1):111-5.
Sarah L. Pett, John Zaunders, Michelle Bailey, John Murray, Karen MacRae, Sean Emery, David A Cooper, Anthony D Kelleher. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CC8+ T-cell numbers in Chronic HIV infection. AIDS Res Hum Retroviruses. 2010 Jun;26(6):653-61.
Dwyer DE; INSIGHT Influenza Study Group. Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.Vaccine. 2011 Jul 22;29 Suppl 2:B56-62.
ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, Early Online Publication, 10 February 2014.